Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 125

1.

Novel protein and immune response markers of human serous tubal intraepithelial carcinoma of the ovary.

Gutkin DW, Shurin MR, El Azher MA, Shurin GV, Velikokhatnaya L, Prosser D, Shin N, Modugno F, Stemmer P, Elishaev E, Lokshin A.

Cancer Biomark. 2019 Oct 18. doi: 10.3233/CBM-190528. [Epub ahead of print]

PMID:
31658047
2.

Biomarker panel for early detection of endometrial cancer in the Prostate, Lung, Colorectal, and Ovarian cancer screening trial.

Tarney CM, Wang G, Bateman NW, Conrads KA, Zhou M, Hood BL, Loffredo J, Tian C, Darcy KM, Hamilton CA, Casablanca Y, Lokshin A, Conrads TP, Maxwell GL.

Am J Obstet Gynecol. 2019 Nov;221(5):472.e1-472.e10. doi: 10.1016/j.ajog.2019.06.005. Epub 2019 Jul 4.

PMID:
31279844
3.

Osteopontin, Macrophage Migration Inhibitory Factor and Anti-Interleukin-8 Autoantibodies Complement CA125 for Detection of Early Stage Ovarian Cancer.

Guo J, Yang WL, Pak D, Celestino J, Lu KH, Ning J, Lokshin AE, Cheng Z, Lu Z, Bast RC Jr.

Cancers (Basel). 2019 Apr 28;11(5). pii: E596. doi: 10.3390/cancers11050596.

4.

Melanoma-Induced Reprogramming of Schwann Cell Signaling Aids Tumor Growth.

Shurin GV, Kruglov O, Ding F, Lin Y, Hao X, Keskinov AA, You Z, Lokshin AE, LaFramboise WA, Falo LD Jr, Shurin MR, Bunimovich YL.

Cancer Res. 2019 May 15;79(10):2736-2747. doi: 10.1158/0008-5472.CAN-18-3872. Epub 2019 Mar 26.

PMID:
30914431
5.

Inflammatory biomarker in adipose stem cells of women with endometrial cancer.

Linkov F, Goughnour SL, Adambekov S, Lokshin A, Kelley JL, Sukumvanich P, Comerci JT, Marra KG, Kokai LE, Rubin JP, Vlad AM, Philips BJ, Edwards RP.

Biomark Med. 2018 Sep;12(9):945-952. doi: 10.2217/bmm-2017-0355. Epub 2018 Jul 25.

6.

Changes in inflammatory endometrial cancer risk biomarkers in individuals undergoing surgical weight loss.

Linkov F, Goughnour SL, Ma T, Xu Z, Edwards RP, Lokshin AE, Ramanathan RC, Hamad GG, McCloskey C, Bovbjerg DH.

Gynecol Oncol. 2017 Oct;147(1):133-138. doi: 10.1016/j.ygyno.2017.07.144. Epub 2017 Aug 7.

7.

Multi-institutional Validation Study of Pancreatic Cyst Fluid Protein Analysis for Prediction of High-risk Intraductal Papillary Mucinous Neoplasms of the Pancreas.

Al Efishat MA, Attiyeh MA, Eaton AA, Gönen M, Prosser D, Lokshin AE, Castillo CF, Lillemoe KD, Ferrone CR, Pergolini I, Mino-Kenudson M, Rezaee N, Dal Molin M, Weiss MJ, Cameron JL, Hruban RH, D'Angelica MI, Kingham TP, DeMatteo RP, Jarnagin WR, Wolfgang CL, Allen PJ.

Ann Surg. 2018 Aug;268(2):340-347. doi: 10.1097/SLA.0000000000002421.

8.

Endometrial cancer associated biomarkers in bariatric surgery candidates: exploration of racial differences.

Linkov F, Goughnour SL, Edwards RP, Lokshin A, Ramanathan RC, Hamad GG, McCloskey C, Bovbjerg DH.

Surg Obes Relat Dis. 2017 May;13(5):862-868. doi: 10.1016/j.soard.2017.01.024. Epub 2017 Jan 13.

9.

BAFF and APRIL from Activin A-Treated Dendritic Cells Upregulate the Antitumor Efficacy of Dendritic Cells In Vivo.

Shurin MR, Ma Y, Keskinov AA, Zhao R, Lokshin A, Agassandian M, Shurin GV.

Cancer Res. 2016 Sep 1;76(17):4959-69. doi: 10.1158/0008-5472.CAN-15-2668. Epub 2016 Jun 30.

10.

Withaferin A inhibits in vivo growth of breast cancer cells accelerated by Notch2 knockdown.

Kim SH, Hahm ER, Arlotti JA, Samanta SK, Moura MB, Thorne SH, Shuai Y, Anderson CJ, White AG, Lokshin A, Lee J, Singh SV.

Breast Cancer Res Treat. 2016 May;157(1):41-54. doi: 10.1007/s10549-016-3795-y. Epub 2016 Apr 21.

11.

Quantification of autoantibodies to plasminogen in plasma of patients with cancer.

Goufman EI, Iakovlev VN, Tikhonova NB, Lokshin AE.

Cancer Biomark. 2015;15(3):281-7. doi: 10.3233/CBM-150469.

PMID:
25769452
12.

Cross-species antibody microarray interrogation identifies a 3-protein panel of plasma biomarkers for early diagnosis of pancreas cancer.

Mirus JE, Zhang Y, Li CI, Lokshin AE, Prentice RL, Hingorani SR, Lampe PD.

Clin Cancer Res. 2015 Apr 1;21(7):1764-71. doi: 10.1158/1078-0432.CCR-13-3474. Epub 2015 Jan 14.

13.

Tumor-associated Neutrophils and Malignant Progression in Intraductal Papillary Mucinous Neoplasms: An Opportunity for Identification of High-risk Disease.

Sadot E, Basturk O, Klimstra DS, Gönen M, Lokshin A, Do RK, D'Angelica MI, DeMatteo RP, Kingham TP, Jarnagin WR, Allen PJ.

Ann Surg. 2015 Dec;262(6):1102-7. doi: 10.1097/SLA.0000000000001044.

14.

Urinary protein biomarkers in the early detection of lung cancer.

Nolen BM, Lomakin A, Marrangoni A, Velikokhatnaya L, Prosser D, Lokshin AE.

Cancer Prev Res (Phila). 2015 Feb;8(2):111-9. doi: 10.1158/1940-6207.CAPR-14-0210. Epub 2014 Nov 21.

15.

The design and methods of genetic studies on acute and chronic postoperative pain in patients after total knee replacement.

Belfer I, Greco CM, Lokshin A, Vulakovich K, Landsittel D, Dai F, Crossett L, Chelly JE.

Pain Med. 2014 Sep;15(9):1590-602. doi: 10.1111/pme.12487. Epub 2014 Jul 8.

16.

Circulating mediators of inflammation and immune activation in AIDS-related non-hodgkin lymphoma.

Nolen BM, Breen EC, Bream JH, Jenkins FJ, Kingsley LA, Rinaldo CR, Lokshin AE.

PLoS One. 2014 Jun 12;9(6):e99144. doi: 10.1371/journal.pone.0099144. eCollection 2014.

17.

Distinct age-matched serum biomarker profiles in patients with cutaneous T-cell lymphoma.

Geskin LJ, Akilov OE, Lin Y, Lokshin AE.

Exp Dermatol. 2014 Aug;23(8):598-600. doi: 10.1111/exd.12455. Epub 2014 Jul 16.

18.

Prediagnostic serum biomarkers as early detection tools for pancreatic cancer in a large prospective cohort study.

Nolen BM, Brand RE, Prosser D, Velikokhatnaya L, Allen PJ, Zeh HJ, Grizzle WE, Huang Y, Lomakin A, Lokshin AE.

PLoS One. 2014 Apr 18;9(4):e94928. doi: 10.1371/journal.pone.0094928. eCollection 2014. Erratum in: PLoS One. 2015;10(2):e0117876. Huang, Ying [added].

19.

Antagonism of tumoral prolactin receptor promotes autophagy-related cell death.

Wen Y, Zand B, Ozpolat B, Szczepanski MJ, Lu C, Yuca E, Carroll AR, Alpay N, Bartholomeusz C, Tekedereli I, Kang Y, Rupaimoole R, Pecot CV, Dalton HJ, Hernandez A, Lokshin A, Lutgendorf SK, Liu J, Hittelman WN, Chen WY, Lopez-Berestein G, Szajnik M, Ueno NT, Coleman RL, Sood AK.

Cell Rep. 2014 Apr 24;7(2):488-500. doi: 10.1016/j.celrep.2014.03.009. Epub 2014 Apr 3.

20.

An exploratory investigation of links between changes in adipokines and quality of life in individuals undergoing weight loss interventions: possible implications for cancer research.

Linkov F, Burke LE, Komaroff M, Edwards RP, Lokshin A, Styn MA, Tseytlin E, Freese KE, Bovbjerg DH.

Gynecol Oncol. 2014 Apr;133(1):67-72. doi: 10.1016/j.ygyno.2014.01.019. Epub 2014 Jan 22.

21.

An extensive targeted proteomic analysis of disease-related protein biomarkers in urine from healthy donors.

Nolen BM, Orlichenko LS, Marrangoni A, Velikokhatnaya L, Prosser D, Grizzle WE, Ho K, Jenkins FJ, Bovbjerg DH, Lokshin AE.

PLoS One. 2013 May 28;8(5):e63368. doi: 10.1371/journal.pone.0063368. Print 2013.

22.

Biomarker testing for ovarian cancer: clinical utility of multiplex assays.

Nolen BM, Lokshin AE.

Mol Diagn Ther. 2013 Jun;17(3):139-46. doi: 10.1007/s40291-013-0027-6. Review.

23.

Circulating prolactin levels and risk of epithelial ovarian cancer.

Clendenen TV, Arslan AA, Lokshin AE, Liu M, Lundin E, Koenig KL, Berrino F, Hallmans G, Idahl A, Krogh V, Lukanova A, Marrangoni A, Muti P, Nolen BM, Ohlson N, Shore RE, Sieri S, Zeleniuch-Jacquotte A.

Cancer Causes Control. 2013 Apr;24(4):741-8. doi: 10.1007/s10552-013-0156-6. Epub 2013 Feb 3.

24.

Oxidants and not alkylating agents induce rapid mtDNA loss and mitochondrial dysfunction.

Furda AM, Marrangoni AM, Lokshin A, Van Houten B.

DNA Repair (Amst). 2012 Aug 1;11(8):684-92. doi: 10.1016/j.dnarep.2012.06.002. Epub 2012 Jul 4.

25.

International Conference on Ovarian Cancer Screening: 29th-30th November 2011, Royal College of Physicians, London. Foreword.

Menon U, Kalsi J, Jacobs I; Scientific Committee Members, Manchanda R, Beller U, Mould T, Skates S, Lokshin A.

Int J Gynecol Cancer. 2012 May;22 Suppl 1:S1. doi: 10.1097/IGC.0b013e3182557e41. No abstract available.

PMID:
22543910
26.

Differential diagnosis of a pelvic mass: improved algorithms and novel biomarkers.

Bast RC Jr, Skates S, Lokshin A, Moore RG.

Int J Gynecol Cancer. 2012 May;22 Suppl 1:S5-8. doi: 10.1097/IGC.0b013e318251c97d.

27.

The quest for ovarian cancer screening biomarkers: are we on the right road?

Lokshin AE.

Int J Gynecol Cancer. 2012 May;22 Suppl 1:S35-40. doi: 10.1097/IGC.0b013e318251ccaa.

PMID:
22543919
28.

Multianalyte assay systems in the differential diagnosis of ovarian cancer.

Nolen BM, Lokshin AE.

Expert Opin Med Diagn. 2012 Mar;6(2):131-138.

29.

A multiplexed serum biomarker immunoassay panel discriminates clinical lung cancer patients from high-risk individuals found to be cancer-free by CT screening.

Bigbee WL, Gopalakrishnan V, Weissfeld JL, Wilson DO, Dacic S, Lokshin AE, Siegfried JM.

J Thorac Oncol. 2012 Apr;7(4):698-708. doi: 10.1097/JTO.0b013e31824ab6b0.

30.

Serum biomarker profiles as diagnostic tools in lung cancer.

Nolen BM, Langmead CJ, Choi S, Lomakin A, Marrangoni A, Bigbee WL, Weissfeld JL, Wilson DO, Dacic S, Siegfried JM, Lokshin AE.

Cancer Biomark. 2011-2012;10(1):3-12. doi: 10.3233/CBM-2012-0229.

31.

Longitudinal evaluation of cancer-associated biomarkers before and after weight loss in RENEW study participants: implications for cancer risk reduction.

Linkov F, Maxwell GL, Felix AS, Lin Y, Lenzner D, Bovbjerg DH, Lokshin A, Hennon M, Jakicic JM, Goodpaster BH, DeLany JP.

Gynecol Oncol. 2012 Apr;125(1):114-9. doi: 10.1016/j.ygyno.2011.12.439. Epub 2011 Dec 22.

32.

Protein biomarkers of ovarian cancer: the forest and the trees.

Nolen BM, Lokshin AE.

Future Oncol. 2012 Jan;8(1):55-71. doi: 10.2217/fon.11.135. Review.

33.

Factors associated with inflammation markers, a cross-sectional analysis.

Clendenen TV, Koenig KL, Arslan AA, Lukanova A, Berrino F, Gu Y, Hallmans G, Idahl A, Krogh V, Lokshin AE, Lundin E, Muti P, Marrangoni A, Nolen BM, Ohlson N, Shore RE, Sieri S, Zeleniuch-Jacquotte A.

Cytokine. 2011 Dec;56(3):769-78. doi: 10.1016/j.cyto.2011.09.013. Epub 2011 Oct 19.

34.

-The advancement of biomarker-based diagnostic tools for ovarian, breast, and pancreatic cancer through the use of urine as an analytical biofluid.

Nolen BM, Lokshin AE.

Int J Biol Markers. 2011 Jul-Sep;26(3):141-52. doi: 10.5301/JBM.2011.8613. Epub 2011 Sep 21. Review.

35.

Inflammatory signaling compromises cell responses to interferon alpha.

Huangfu WC, Qian J, Liu C, Liu J, Lokshin AE, Baker DP, Rui H, Fuchs SY.

Oncogene. 2012 Jan 12;31(2):161-72. doi: 10.1038/onc.2011.221. Epub 2011 Jun 13.

36.

Circulating inflammation markers and risk of epithelial ovarian cancer.

Clendenen TV, Lundin E, Zeleniuch-Jacquotte A, Koenig KL, Berrino F, Lukanova A, Lokshin AE, Idahl A, Ohlson N, Hallmans G, Krogh V, Sieri S, Muti P, Marrangoni A, Nolen BM, Liu M, Shore RE, Arslan AA.

Cancer Epidemiol Biomarkers Prev. 2011 May;20(5):799-810. doi: 10.1158/1055-9965.EPI-10-1180. Epub 2011 Apr 5.

37.

A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer.

Zhu CS, Pinsky PF, Cramer DW, Ransohoff DF, Hartge P, Pfeiffer RM, Urban N, Mor G, Bast RC Jr, Moore LE, Lokshin AE, McIntosh MW, Skates SJ, Vitonis A, Zhang Z, Ward DC, Symanowski JT, Lomakin A, Fung ET, Sluss PM, Scholler N, Lu KH, Marrangoni AM, Patriotis C, Srivastava S, Buys SS, Berg CD; PLCO Project Team.

Cancer Prev Res (Phila). 2011 Mar;4(3):375-83. doi: 10.1158/1940-6207.CAPR-10-0193.

38.

Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens.

Cramer DW, Bast RC Jr, Berg CD, Diamandis EP, Godwin AK, Hartge P, Lokshin AE, Lu KH, McIntosh MW, Mor G, Patriotis C, Pinsky PF, Thornquist MD, Scholler N, Skates SJ, Sluss PM, Srivastava S, Ward DC, Zhang Z, Zhu CS, Urban N.

Cancer Prev Res (Phila). 2011 Mar;4(3):365-74. doi: 10.1158/1940-6207.CAPR-10-0195.

39.

Serum biomarker panels for the detection of pancreatic cancer.

Brand RE, Nolen BM, Zeh HJ, Allen PJ, Eloubeidi MA, Goldberg M, Elton E, Arnoletti JP, Christein JD, Vickers SM, Langmead CJ, Landsittel DP, Whitcomb DC, Grizzle WE, Lokshin AE.

Clin Cancer Res. 2011 Feb 15;17(4):805-16. doi: 10.1158/1078-0432.CCR-10-0248.

40.

Temporal reliability of cytokines and growth factors in EDTA plasma.

Clendenen TV, Arslan AA, Lokshin AE, Idahl A, Hallmans G, Koenig KL, Marrangoni AM, Nolen BM, Ohlson N, Zeleniuch-Jacquotte A, Lundin E.

BMC Res Notes. 2010 Nov 13;3:302. doi: 10.1186/1756-0500-3-302.

41.

Circulating cytokines and risk of B-cell non-Hodgkin lymphoma: a prospective study.

Gu Y, Shore RE, Arslan AA, Koenig KL, Liu M, Ibrahim S, Lokshin AE, Zeleniuch-Jacquotte A.

Cancer Causes Control. 2010 Aug;21(8):1323-33. doi: 10.1007/s10552-010-9560-3. Epub 2010 Apr 7.

42.

Development of a multimarker assay for early detection of ovarian cancer.

Yurkovetsky Z, Skates S, Lomakin A, Nolen B, Pulsipher T, Modugno F, Marks J, Godwin A, Gorelik E, Jacobs I, Menon U, Lu K, Badgwell D, Bast RC Jr, Lokshin AE.

J Clin Oncol. 2010 May 1;28(13):2159-66. doi: 10.1200/JCO.2008.19.2484. Epub 2010 Apr 5.

43.

Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass.

Nolen B, Velikokhatnaya L, Marrangoni A, De Geest K, Lomakin A, Bast RC Jr, Lokshin A.

Gynecol Oncol. 2010 Jun;117(3):440-5. doi: 10.1016/j.ygyno.2010.02.005. Epub 2010 Mar 24.

44.

Lung cancer stem cells as a target for therapy.

Gorelik E, Lokshin A, Levina V.

Anticancer Agents Med Chem. 2010 Feb;10(2):164-71. Review.

PMID:
20184538
45.

Cell-based and cytokine-directed chemical screen to identify potential anti-multiple myeloma agents.

Feng R, Rios JA, Onishi T, Lokshin A, Gorelik E, Lentzsch S.

Leuk Res. 2010 Jul;34(7):917-24. doi: 10.1016/j.leukres.2009.12.002. Epub 2010 Feb 8.

PMID:
20116850
46.

Targeting CCL11 in the treatment of ovarian cancer.

Nolen BM, Lokshin AE.

Expert Opin Ther Targets. 2010 Feb;14(2):157-67. doi: 10.1517/14728220903512983. Review.

PMID:
20055715
47.
48.

Screening for ovarian cancer: old tools, new lessons.

Nolen BM, Lokshin AE.

Cancer Biomark. 2010-2011;8(4-5):177-86. doi: 10.3233/CBM-2011-0210. Review.

PMID:
22045352
49.

Elimination of human lung cancer stem cells through targeting of the stem cell factor-c-kit autocrine signaling loop.

Levina V, Marrangoni A, Wang T, Parikh S, Su Y, Herberman R, Lokshin A, Gorelik E.

Cancer Res. 2010 Jan 1;70(1):338-46. doi: 10.1158/0008-5472.CAN-09-1102. Epub 2009 Dec 22.

50.

Pancreatic cyst fluid protein expression profiling for discriminating between serous cystadenoma and intraductal papillary mucinous neoplasm.

Allen PJ, Qin LX, Tang L, Klimstra D, Brennan MF, Lokshin A.

Ann Surg. 2009 Nov;250(5):754-60. doi: 10.1097/SLA.0b013e3181bd7f20.

Supplemental Content

Loading ...
Support Center